Roche’s bispecific antibody, Columvi receives European approval for diffuse large B-cell lymphoma after initial therapy: Basel Tuesday, April 15, 2025, 10:00 Hrs [IST] Roche ann ...

ECHELON-3 (NCT04404283) principal investigator Craig A. Portell, MD, speaks to the significance of this triplet approval from ...

For example, one of the most common treatments for diffuse large B-cell lymphoma is R-CHOP. This combines a drug called rituximab (Riabni, Rituxan, Ruxience, Truxima) with three chemotherapy drugs ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas ... in combination with rituximab, a monoclonal antibody that helps further target the CAR-NK cells to lymphoma cells.

Discover how innovative lymphoma treatments are transforming patient outcomes, from targeted therapies to immunotherapy ...

The patient was diagnosed with nongerminal-center B cell diffuse large B-cell lymphoma (DLBCL) 1 year after being diagnosed with primary biliary cholangitis (PBC).

Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk of death compared to MabThera/Rituxan plus chemotherapy1,2 DLBCL is an ...

A majority of cases of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma globally, are ...

Innovative polatuzumab vedotin plus R-CHP therapy reshapes treatment of older adult patients with diffuse large B-cell lymphoma.

The approval of the Columvi combo, the first bispecific antibody regimen for DLBCL in Europe, follows a conditional marketing ...